Vanda Pharmaceuticals Inc.


Brean Capital Take on Vanda Pharmaceuticals Inc.’s (VNDA) Patent Win; Raises Price Target to $24

Brean Capital analyst Difei Yang was out today with a few insights on Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), following the news that the U.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts